SCHEMBL3783390

SCHEMBL3783390

CCOc1cc(N)ccc1-c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.53
KDM4E B2RXH2 3/20 0.53
GAA P10253 2/20 0.53
CYP19A1 P11511 1/20 0.52
CYP11B1 P15538 1/20 0.52
CYP11B2 P19099 1/20 0.52
PTGDR2 Q9Y5Y4 1/20 0.49
ALDH1A1 P00352 4/20 0.47
PTPRC P08575 1/20 0.45
NCOA1 Q15788 1/20 0.45
NCOA3 Q9Y6Q9 1/20 0.45
MAPK1 P28482 3/20 0.44
HPGD P15428 2/20 0.44
TP53 P04637 2/20 0.44
CYP3A4 P08684 1/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
KMT2A Q03164 1/20 0.44
HSD17B10 Q99714 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30427138 0.89 MAPT (0.56) MAPTKDM4EGAACYP19A1CYP11B1
SCHEMBL2210399 0.89 MAPT (0.56) MAPTKDM4EGAACYP19A1CYP11B1
SCHEMBL3790341 0.88 MAPT (0.51) MAPTKDM4EGAACYP19A1CYP11B1
SCHEMBL27902946 0.87 TP53 (0.54) MAPTKDM4EGAACYP19A1CYP11B1
SCHEMBL3789504 0.86 PTGDR2 (0.65) MAPTKDM4EGAAPTGDR2ALDH1A1
SCHEMBL347279 0.85 MAPT (0.63) MAPTKDM4EGAACYP19A1CYP11B1
SCHEMBL8897316 0.83 CYP11B1 (0.56) KDM4ECYP19A1CYP11B1CYP11B2PTGDR2
SCHEMBL27324840 0.82 EGFR (0.56) MAPTKDM4EALDH1A1PTPRCMAPK1
SCHEMBL27920645 0.82 ALDH1A1 (0.61) MAPTKDM4EGAACYP19A1CYP11B1
SCHEMBL3791209 0.81 CYP19A1 (0.74) MAPTGAACYP19A1CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103097353-B Immunomodulator and anti-inflammatory compound INCOZEN THERAPEUTICS PVT LTD 2015-03-04 CN disclosed
CN-103097353-A Novel immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT LTD 2013-05-08 CN disclosed
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 MAPT 3312/4885KDM4E 2606/4885GAA 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.